טוען...
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
BACKGROUND: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is defined as a rising prostate-specific antigen concentration, despite castrate levels of testosterone with ongoing androgen-deprivation therapy or orchiectomy, and no detectable metastases by conventional imaging. Patients wit...
שמור ב:
| הוצא לאור ב: | Prostate Cancer Prostatic Dis |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8134049/ https://ncbi.nlm.nih.gov/pubmed/33558665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-020-00310-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|